Oxford Biomedica acquires Chiron patents
Oxford BioMedica has signed an agreement with Chiron to acquire certain patent families from Chiron's gene therapy patent portfolio
The agreement includes taking assignment of Chiron's interest in a license agreement with an undisclosed university.
Financial terms have not been disclosed.
Chiron's patent portfolio contains some early gene therapy technology that complements Oxford BioMedica's substantial gene therapy patent estate.
The technology acquired includes:.
1 - The use of human cell lines for the production of gene therapy products.
2 - Gene-directed enzyme pro-drug therapy (GDEPT).
3 - The use of the envelope protein of the vesicular stomatis virus (VSV-g) for increasing the ability of gene therapy vectors to transduce a broad range of human cell types.
Under a separate agreement, Chiron has made an equity investment in Oxford BioMedica subscribing for a total of 316,026 ordinary shares of 1p each at 17.23 pence per share.
Commenting on these agreements the company's senior vice president for commercial development, Peter Nolan, said: "We are delighted to have concluded this agreement with Chiron and welcome them as shareholders in the company".
"Securing this intellectual property will enhance our competitive position in gene therapy and in the use of our technology in drug discovery."
The rights granted are exclusive for RNAi gene silencing using lentiviral vector technology for human gene therapy applications, including Oxford BioMedica's proprietary LentiVector system
Oxford BioMedica and Sanofi-Aventis have entered into an exclusive global licensing agreement to develop and commercialise Trovax for the treatment and prevention of cancers
Acquisition of privately held biotechnology company, based in Oxford, UK, adds melanoma cancer vaccine and extends immunotherapy platform
Oxford BioMedica, Viragen , and Roslin Institute, announce the successful expression of human interferon alpha-2a in the whites of eggs laid by transgenic hens using the Ova system
Oxford BioMedica reports that the Phase III Trist trial of its novel cancer immunotherapy, TroVax, in patients with renal cancer, has been adopted by the UK National Cancer Research Network (NCRN)